Overview
The Selank / Semax Blend combines two of the most extensively studied Russian neuropeptides into a single research formulation. Selank (a synthetic heptapeptide derived from the endogenous immune peptide tuftsin) provides GABAergic anxiolysis and immune modulation, while Semax (an ACTH(4-7) Pro-Gly-Pro analog) drives BDNF upregulation and neuroprotective signaling. Together they target complementary but non-overlapping pathways: Selank quiets the stress-anxiety axis while Semax amplifies cognitive performance and neuroplasticity — a dual-mechanism approach that neither compound achieves alone.
Mechanism of Action
The Selank / Semax Blend operates through two parallel and synergistic neurochemical pathways. Selank's primary mechanism involves positive allosteric modulation of GABA-A receptors, enhancing inhibitory neurotransmission in a manner mechanistically similar to benzodiazepines but without the receptor downregulation, sedation, or tolerance induction associated with classical GABA-A agonists. Selank also upregulates BDNF expression in the hippocampus and prefrontal cortex, modulates serotonin metabolism (increasing 5-HT turnover), and retains the immunomodulatory properties of its parent peptide tuftsin, which activates macrophages and NK cells via Fc receptor binding. Semax operates through a
Research Evidence
- Selank completed Phase III clinical trials in Russia for generalized anxiety disorder and demonstrated anxiolytic efficacy comparable to benzodiazepines without sedation, dependence, or withdrawal (Zozulya et al., 2001)
- Semax is registered as a pharmaceutical drug in Russia (since 1994) and is used clinically for ischemic stroke recovery, cognitive impairment, and optic nerve disease — one of the most clinically validated peptides in this catalog
- Selank upregulates BDNF mRNA expression in the hippocampus by approximately 1.4-fold in rodent models, while Semax produces BDNF upregulation of 1.6-fold — suggesting additive neuroplastic effects when combined (Dolotov et al., 2006; Semenova et al., 2009)
- The NMDA receptor glycine site modulation shared by both Selank and Semax (Gudasheva et al., 2023) provides a mechanistic basis for their synergistic cognitive effects, particularly in models of cognitive deficit
- Selank's tuftsin-derived immunomodulatory activity (IL-6 normalization, NK cell activation) complements Semax's neuroprotective effects, potentially supporting neuroimmune homeostasis in stress models
Bottom line: This is one of the most mechanistically well-justified blends in the research peptide space. Both compounds have substantial peer-reviewed literature and real clinical use histories. The combination logic is sound: complementary, non-overlapping pathways with additive BDNF effects. The main research gap is dedicated combination studies. Research-only compound — not approved for human use.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for Selank/Semax Blend are detailed in the full compound profile. See also: Dosage guide for Selank/Semax Blend.
Sourcing & Quality
Selank/Semax Blend is available from Purgo Labs with third-party COA verification and research-grade purity standards. View Selank/Semax Blend at Purgo Labs.